Home › Foundation Medicine Gets NY State Approval for Liquid Biopsy Test

Foundation Medicine Gets NY State Approval for Liquid Biopsy Test

Oct 02, 2017

NEW YORK (GenomeWeb) – Foundation Medicine said today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its FoundationACT blood-based circulating tumor DNA assay. All of its genomic profiling tests are now available in all 50 states, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  2. Digital Pathology Startup Deep Lens Emerges From Stealth Mode

  3. DiaCarta Lands $2M SBIR Grant to Develop Radiation Toxicity Assay

  4. AmoyDx Lung Cancer CDx Approved in South Korea

  5. Precipio Reports 140 Percent Jump in Preliminary Q3 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.